TempraMed Technologies (TMPTF) signed an exclusive UK distribution agreement with Poole Bay Holdings for VIVI Epi, covering an initial 24-month term.
The definitive agreement, signed October 28, 2026 through wholly owned subsidiary TempraMed Israel, sets minimum annual purchase targets to retain exclusivity. The initial two-year targets represent approximately US$198,000 in potential purchases, not completed sales. The first purchase order must be paid in full before shipment.
VIVI Epi provides passive temperature protection for compatible epinephrine auto-injectors. Poole Bay's channels include specialist business-to-business e-commerce and a network of 15,000 UK schools. TempraMed plans launch sampling and eligible co-marketing support. Commercial sales remain subject to applicable UK regulatory registrations and requirements, with rollout dependent on launch execution and market adoption.
TempraMed Technologies (TMPTF) signed an exclusive distribution agreement with SPORTORO covering medication-protection products in Croatia, Serbia and Bosnia and Herzegovina. Signed through TempraMed Israel and dated October 19, 2026, the agreement covers VIVI Cap, VIVI Epi and VIVI Med for an initial 36 months.
Annual minimum purchase targets imply approximately US$550,000 over that term, assuming an all-VIVI Cap mix at current pricing; realized value depends on product mix, volumes, approvals and performance. An initial order is to be placed and fully paid upon execution, with a second targeted within six months of the initial order. SPORTORO funds market development and obtains country-specific licenses and regulatory approvals at its expense. Exclusivity depends on performance and other conditions; renewals require performance and mutual agreement. TempraMed launch support is conditional.
TempraMed Technologies (TMPTF) has executed an exclusive Kuwait distribution agreement with OGM For Import Medicine and Medical Supplies. Dated September 14, 2026, the agreement has an initial 36-month term and includes minimum annual purchase commitments representing approximately US$500,000 in potential minimum purchases over that term.
Purchases are subject to regulatory clearance, continued compliance with the agreement and fulfillment of applicable purchase commitments. OGM will handle registration, marketing, promotion, sales and distribution in Kuwait for a portfolio including VIVI Cap, VIVI Cap Smart, VIVI Med and VIVI Epi. TempraMed says the agreement supports its strategy of expanding through exclusive international distribution partners in high-temperature markets.
TempraMed (TMPTF) has secured a Mexican patent covering core innovations in its VIVI Box multi-medication storage platform, which has not yet launched.
Patent application MX/a/2021/004595 was formally granted by the Mexican Patent Office, with protection extending through October 24, 2039. Its claims include elements of the platform's thermal-insulation and smart-monitoring architecture. TempraMed views the grant as supporting its commercialization strategy and engagement with appliance manufacturers. The grant follows similar patents in South Korea and China and several distribution agreements.
TempraMed Technologies (TMPTF) announced that its VIVI Cap Smart platform now supports connectivity with Apple Health and Google Fit.
The connected temperature-protection device is designed for insulin pens, GLP-1 therapies and other injectable medications. Its digital capabilities are designed to capture injection activity and temperature exposure, provide medication reminders and share medication-use information with caregivers and healthcare professionals. The platform is designed to work across multiple pen brands and therapy categories.
VIVI Cap Smart uses a connected-device and subscription model, with potential software-enabled revenue alongside hardware sales. TempraMed's broader smart-platform roadmap includes connected solutions for epinephrine auto-injectors, vials, biologics and multi-medication storage formats.
TempraMed Technologies (TMPTF) closed a non-brokered private placement of convertible debt and share units, raising gross proceeds of $1,177,940.
The offering comprised $600,000 of unsecured convertible debentures and 1,155,880 units, each containing one common share and one warrant. The debt bears 10% annual interest, payable quarterly in cash, and matures September 30, 2027. Holders may convert principal into shares at $0.50 per share through maturity. Each warrant permits purchase of one share at C$1.00 through March 30, 2028.
Proceeds will fund inventory, product development, global sales and marketing expansion, and working capital. TempraMed paid $40,456 in finder's fees and issued 80,912 common shares to finders.
TempraMed (TMPTF) signed a non-binding letter of intent with CPO Cyprus for proposed exclusive distribution of VIVI Cap and VIVI Epi in Cyprus.
The letter is dated July 31, 2026. Exclusivity would depend on a definitive agreement and minimum purchase obligations. To retain it, CPO Cyprus would have to increase combined annual purchases of the two products by at least 20% year over year. Transfer prices and the first-year minimum combined unit commitment are to be established in the definitive agreement. The parties have 90 days from July 31 to conclude that agreement, unless they mutually extend the period.
TempraMed (TMPTF) has upsized its proposed private placement to raise up to C$1.6 million through convertible debentures and units. The offering comprises up to C$600,000 in unsecured debentures and up to C$1 million in units. Each unit contains one common share and one warrant to buy another share for C$1.00 within 18 months of closing.
The debentures carry 10% annual interest, payable quarterly in cash, and mature one year after issuance. Holders may convert principal into shares at $0.50 per share; at maturity, they may also convert accrued, unpaid interest. TempraMed plans to use proceeds for inventory, product development, global sales and marketing expansion, and working capital. The offering remains subject to CSE approval and required filings.
TempraMed (TMPTF) expanded its TEM distribution agreement into four more Latin American countries under an amendment dated September 23, 2026.
The exclusive distribution relationship now covers Argentina, Venezuela, Colombia and Costa Rica alongside Panama. It also adds VIVI Med to the covered products, with VIVI Cap and VIVI Epi. The amendment includes an initial order for the added countries, with TEM choosing the product mix. TempraMed received a separate additional commercial order from TEM that it expects to fulfill by the end of September 2026. With separate initiatives in Brazil and Mexico, the company expects distribution relationships to cover seven countries once required registrations and launch activities are completed.
TempraMed also proposes a private placement of up to 2 million units at C$0.50 each, for up to C$1 million in gross proceeds. Each unit contains one common share and one warrant to buy another share at C$1.00 within 18 months after closing.
TempraMed Technologies (TMPTF) entered into a distribution agreement with CenterWell Pharmacy, the pharmacy services brand of U.S. health insurer Humana, dated August 25, 2026.
The company develops medical-technology solutions for storing and managing temperature-sensitive medications and expects CenterWell to distribute its products in the United States.